AMT-061

fidanacogene elaparvovec · CSL Behring

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AMT-061, covering 2022-10-10 to 2022-10-10. Get the full timeline:

Most recent: Clinical Trial Update: HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients [Phase 3]